In conclusion, the present study has shown that oxybutynin and propiverine, after oral administration, bind significantly to muscarinic receptors in tissues such as the bladder, which is the target organ for the treatment of urinary incontinence, and that oxybutynin appears to exhibit long-term binding to muscarinic receptors in the salivary gland.
Urinary incontinence and other symptoms of lower urinary tract dysfunction are very common in the rapidly growing geriatric population. Urge urinary incontinence with bladder instability (detrusor instability or detrusor hyperreflexia) is among the most common type of incontinence in geriatric patients. 1) Anticholinergic drugs, such as oxybutynin, are widely used to treat this symptom since parasympathetic innervation is the predominant stimulus for bladder contraction.
2) However, anticholinergic drugs can cause problems in geriatric patients because of their side effects, such as dry mouth, blurred vision, constipation and tachycardia.
3) The majority of both the beneficial and unwanted effects of these drugs in patients with bladder instability stems from the blockade of musarinic receptors in target (bladder) and nontarget tissues. In an attempt to reduce serious side-effects, such as dry mouth, a number of compounds have been synthesized and evaluated in terms of pharmacological specificity in the bladder relative to the parotid gland. 4, 5) Also, a new drug delivery system for oxybutynin has been used clinically and found to be an effective dosage form. 6) Although there are many studies dealing with the pharmacological effects and in vitro receptor binding affinities of anticholinergic agents, 3, [7] [8] [9] very little in vivo data are available regarding the muscarinic receptor binding characteristics (extent and time-course) in tissues following systemic administration of anticholinergic agents. In general, the results of in vitro receptor binding studies of drugs may not necessarily guarantee in vivo pharmacological specificity, such as organ selectivity, because they do not take into account various pharmacokinetic (absorption, distribution and elimination) and pharmacodynamic factors. 10) This was the case for the receptor binding properties of the 1,4-dihydropyridine calcium channel antagonists 11, 12) and a 1 -adrenoceptor antagonists. [13] [14] [15] Thus, the aim of the present study was to characterize the muscarinic receptor binding in rat tissues, such as the bladder, after oral administration of oxybutynin and propiverine, the most commonly used anticholinergic agents for the treatment of patients with detrusor instability and detrusor hyperreflexia. 3 .09 TBq/mmol) was purchased from Dupont-NEN Co., Ltd. (Boston, MA, U.S.A.). Oxybutynin hydrochloride (oxybutynin) and propiverine hydrochloride (propiverine) were generously donated by Meiji Milk Products Co., Ltd. (Odawara, Japan) and Taiho Pharmaceutical Co., Ltd. (Saitama, Japan), respectively. All other chemicals were purchased from commercial sources.
MATERIALS AND METHODS

Materials
Tissue Preparation Male Sprague Dawley rats weighing about 200-300 g were housed, three to four per cage, in the laboratory with free access to food and water, and were maintained on a 12 h dark/light cycle in a room with controlled temperature (24Ϯ2°C) and humidity (55Ϯ5%). They were fasted for 16 h before drug administration, then given propiverine (24.8-297 mmol/kg) or oxybutynin (50.8, 127 mmol/kg) orally in the form of a suspension in distilled water. Control animals were given vehicle alone. At 0.5 to 6 h after drug administration, rats were killed by taking the blood from the descending aorta under temporary anesthesia with diethyl ether, and the tissues were then perfused with cold saline from the aorta. Then, the bladder, prostate, submaxillary gland, heart and cerebral cortex were dissected, and fat and blood vessels removed by trimming. The tissues were minced with scissors and homogenized by a Kinematica Polytron homogenizer in 20 volumes of ice-cold 50 mM Na ϩ /K ϩ phosphate buffer (pH 7.4). The homogenates were centrifuged at 40000ϫg for 20 min and the resulting pellets finally suspended in buffer for the binding assay. In the ex vivo experiment, there is a possibility that oxybutynin and propiverine might partially dissociate from the receptor sites during tissue preparation (homogenization and suspension) after oral administration to rats. Yamada et al. 16) previously showed that the dissociation of antagonists from receptor sites at 4°C was extremely slow. So, to minimize the dissociation of oxybutynin and propiverine from the receptor sites, all steps involved in the tissue preparation were performed at 4°C. In fact, there was no large difference in (Ϫ) 18, 19) The homogenates (90-600 mg of protein) of rat tissues were incubated with different concentrations (0.06-1.5 nM) of (Ϫ)- [ 3 H]QNB in 50 mM of a Na ϩ /K ϩ phosphate buffer (pH 7.4). Incubation was carried out for 60 min at 37°C. The reaction was terminated by rapid filtration (Cell Harvester, Brandel Co., Gaithersburg, MD, U.S.A.) through Whatman GF/B glass fiber filters, and the filters were rinsed three times with 3 ml of ice-cold buffer. Tissue-bound radioactivity was extracted from the filters overnight by immersion in scintillation fluid (21 toluene, 11 Triton X-100, 15 g 2,5-diphenyloxazole, 0.3 g 1,4-bis[2-(5-phenyloxazolyl)]benzene), and the radioactivity was determined in a liquid scintillation counter. Specific (Ϫ)- [ 3 H]QNB binding was determined experimentally from the difference between counts in the absence and presence of 1 mM atropine. All assays were conducted in duplicate.
Data Analysis The analysis of (Ϫ)-[ 3 H]QNB binding data was performed as described previously.
16) The apparent dissociation constant (K d ) and maximal number of binding sites (B max ) for (Ϫ)-[ 3 H]QNB were estimated by Rosenthal analysis of the saturation data. Statistical analysis of the data was performed by a one-way analysis of variance (ANOVA), followed by Dunnett's test for multiple comparison. Statistical significance was accepted at pϽ0.05.
RESULTS
Effects of Oral Administration of Oxybutynin
The effect of oral administration of oxybutynin on specific (Ϫ)- (Table 1 ). In the prostate and submaxillary gland of these rats, the K d values were also significantly increased at 0.5 and 3 h, and the magnitude of this increase was 99-101% (prostate) and 131-138% (submaxillary gland). Furthermore, the significant increases in the K d values in the heart after 3 and 6 h were 75 and 20%, respectively. The B max value for specific (Ϫ)- [ 3 H]QNB binding in each tissue remained largely unchanged except for a significant (20-36%) reduction in the submaxillary gland at 0.5-6 h after oxybutynin administration.
The higher oral dose (127 mmol/kg) of oxybutynin caused a sustained increase in the K d values for (Ϫ)- [ 3 H]QNB binding in each tissue at 0.5, 3 and 6 h, and the magnitude of this increase was 49-87% (bladder), 108-301% (prostate), 163-455% (submaxillary gland) and 37-59% (heart), respectively (Table 2 ). This enhancement, compared with that produced by 50.8 mmol/kg of this drug (Table 1) , was greater in the bladder, prostate and submaxillary gland, but comparable in the heart. In rats given oxybutynin (127 mmol/kg), the B max values were significantly reduced at 6 h in the bladder 492 Vol. 24, No. 5 (Table 4 ). There were constant increases (46-92, 54-115 and 24-72%, respectively) in the K d values in the prostate, submaxillary gland and cerebral cortex 0.5-6 h after propiverine administration, and also an increase (40-91%) in the heart 0.5-3 h. In the heart, there was a significant increase in the B max at 0.5 and 3 h.
DISCUSSION
To date, little information has been published regarding the muscarinic receptor binding characteristics in tissues after oral administration of oxybutynin and propiverine. The technique of ex vivo and in vivo receptor binding is useful for predicting the in vivo potency, organ selectivity, and duration of action of drugs in relation to their pharmacokinetics and pharmacodynamics. [10] [11] [12] [13] [14] [15] In the present study, the ex vivo receptor binding technique was used to simultaneously examine mucarinic receptor binding characteristics in the bladder and other tissues of rats after systemic administration of oxybutynin and propiverine. The oral doses of oxybutynin and propiverine chosen were 50.8 or 127 mmol/kg and 24.8- Values are meanϮS.E. of 3 to 6 rats. Rats received 24.8 to 297 mmol/kg of propiverine orally, and were sacrificed 1 h later. Specific binding of (Ϫ)-[ Values are meanϮS.E. of 3 to 6 rats. Rats received 74.3 mmol/kg of propiverine orally, and were sacrificed 0.5 to 6 h later. Specific binding of (Ϫ)-[ 297 mmol/kg, respectively, because they were expected to produce significant pharmacological effects on the basis of intravenous doses of these drugs in reducing urinary bladder contractions in rat cystometry studies. [20] [21] [22] The oral administration of oxybutynin (50. 8 23) It is speculated that such receptor binding specificity of oxybutynin in the exocrine gland may account, at least in part, for the high incidence of severe dry mouth after oral administration of this drug in patients with urinary incontinence.
3)
The oral administration of propiverine at doses of 74.3-297 mmol/kg produced a considerable increase in the K d values for (Ϫ)- [ 3 H]QNB binding with a significant reduction in the B max (only at the dose of 74.3 mmol/kg) in the rat bladder. Also, a greater increase in the K d values was seen in the rat prostate, heart and submaxillary gland following propiverine administration. Such an increase in each tissue seems to reach a plateau at the dose of 74.3 mmol/kg for this drug. From the time-course of the K d values for (Ϫ)- [ 3 H]QNB binding after propiverine administration, it appears that propiverine may have a more sustained inhibitory effect on the muscarinic receptors in the prostate and submaxillary gland than in the bladder and heart. However, oral administration of propiverine, unlike oxybutynin, produced very little reduction in the B max values for (Ϫ)-[ 3 H]QNB binding in the submaxillary gland. This observation suggests a more reversible binding of propiverine than oxybutynin to the muscarinic receptors in the salivary gland. In connection with this observation, it is of some interest to note that propiverine has less effect on salivation than oxybutynin in conscious dogs, 24) and that propiverine may be better tolerated than oxybutynin, particularly with respect to the frequency and intensity of the episodes of dry mouth in patients with urinary incontinence. 25) The reason for a significant increase in the B max values for (Ϫ)- [ 3 H]QNB binding in the rat heart 0.5 and 3 h after oral administration of propiverine is not clear, but it may reflect up-regulation of myocardial muscarinic receptors as a result of the receptor blockade as previously reported in tissues of atropine-treated rats. 26) Oral administration of oxybutynin and propiverine considerably increased the K d values for cerebral cortical (Ϫ)-[ 3 H]QNB binding with little effect on the B max values, and the effect was more marked in the brain of propiverinetreated rats. These data may indicate that both drugs could easily cross the blood-brain barrier and bind to muscarinic receptor sites in the brain parenchymal cells to a significant degree in vivo. Hence, it is plausible that oxybutynin and propiverine exert some CNS effects in vivo, due to the blockade of brain muscarinic receptors, although, to our knowledge, such anticholinergic effects of these drugs have not been identified directly. In this connection, it is of some interest to note the recent finding by Matsuo et al. 27) that intraperitoneal injection of oxybutynin and propiverine induced catalepsy in mice in a dose-dependent manner and their effects might be closely associated with the in vivo blockade of dopamine and muscarinic receptors in the CNS.
In conclusion, this study has shown that oxybutynin and propiverine, after oral administration, exhibit a significant degree of binding to the muscarinic receptors in tissues such as the bladder, which is the target organ for the treatment of urinary incontinence, and that oxybutynin exhibits longer term occupation of muscarinic receptors in the salivary gland than propiverine. Thus, the present technique, which measures muscarinic receptor binding parameters after treatment with anticholinergic drugs under physiological conditions, may offer a better insight into the organ-selectivity of these drugs than results obtained from in vitro experiments.
